Reduced cancer progression, risk One paper, published in the affiliated Journal of Clinical Oncology in late May, looked at more than 10,000 medical records and found GLP-1 use among cancer patients was linked to dramatically reduced disease progression across multiple types of tumors, including some forms not largely linked to obesity
In a food-effect trial, limited or no measurable semaglutide plasma concentration at steady-state was observed in the fed group, while all subjects in the fasting group had measurable semaglutide concentrations
[1] This means it has not undergone the rigorous testing required for pharmaceutical products, and its quality, purity, and potency may vary considerably between manufacturers
Its transparent pricing model with options starting around $179 per month ensures patients know exactly what to expect, without hidden fees or insurance complications